drugset / Trial / NCT00338273
A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode
Phase 3
Withdrawn
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka America Pharmaceutical · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.
Timeline
- Start
- 2006-12
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aripiprazole | Other / unclassified | 5 mg | Oral |
| Comparator | Aripiprazole | Other / unclassified | 30 mg | Oral |